Excellent work here, with successful results consistent with the published literature on 40 Gy (or less) to the elective neck.

Rising PGY-5s and anyone interested, we have a 5th HN rad onc position Moffitt Cancer Center. If interested in joining a busy team, including me, Dr. M Echevarria, George Q. Yang, MD, and Niema Razavian, MD, reach out and can chat about the position.

Excited to share our latest work in Advances in Radiation Oncology! 🚀 We compared outcomes of 5-fraction adaptive MRI-guided RT for newly diagnosed glioblastoma vs. 15- & 30-fraction regimens using propensity score matching. 📄doi.org/10.1016/j.adro…

Very thoughtful take in this article. One additional comment: if there is any one discipline in US radiation oncology that is disappearing over the next 5 years, it is the dosimetrist/treatment planner. Auto-planning will essentially render this position close to obsolete, with

This is very nice work and has important implications for the use of NavDX (ctHPVDNA by ddPCR) to determine postoperative treatment. During the Mayo DART trial, ctDNA was drawn a median of 22 days after surgery, with 17/140 (12.1%) positive. ALL of these patients then received

David Sher Re: impact of more sensitive NGS assays. We agree. Preliminary results from our Clear-HPVca Trial (NCT NCT06730412) were highly promising (presented at ASCO 2024- ascopubs.org/doi/10.1200/JC…) Final analysis being completed and hope to have results out soon.

David Sher See our commentary on Routman et al here: jamanetwork.com/journals/jamao… JAMA Otolaryngology – Head & Neck Surgery

DART 2, which was based upon this work, should finish accrual Q2 2026, so more data on ctDNA-personalized de-escalation will be available in the near future. Primary manuscript for DART should be out in the next two months as well.

The Force was with us today UTSW Radiation Oncology! We treated our first HANSOLO patient using Ethos: Head And Neck radiotherapy with Simulation Omitted and setup and pLanning Online. Patient needed emergent radiotherapy to control bleeding but may receive definitive treatment later,

I recently saw a patient 9 years following early-stage glottic larynx SAbR (on our original CyberKnife trial). The images below represent the typical endoscopic appearance. Our G-FORCE phase II RCT (LT-SAbR versus whole larynx) is now ~ 33% accrued! clinicaltrials.gov/study/NCT06080…

Dr. Mu-Han Lin presented, "Report on Common Clinical Workflows and Staffing Models for CTgART," in the session of "Staffing Practices for Online ART with CBCT- and MR-Based Platforms." Additionally, Dr. Lin moderated "MR-Guided Radiation Therapy - Expanding the Horizon."

We are excited that our most recent amendment was approved, streamlining imaging criteria for enrollment. EA3211 is a phase III randomized trial comparing consolidative radiotherapy plus pembro with pembro alone in patients with oligometastatic head and neck cancer who have not